Clinic of Surgery, Department of Transplantation and Liver Surgery, Helsinki University Hospital , Helsinki Finland.
Ann Med. 2013 Nov;45(7):482-7. doi: 10.3109/07853890.2013.823779. Epub 2013 Aug 20.
Prediction of prognosis in hepatocellular carcinoma (HCC) is difficult. The aim of this study was to evaluate the prognostic value of serum MMP-8, -9, -13, and TIMP-1 in patients with HCC.
Pre-treatment serum samples from 134 patients with HCC were retrospectively analyzed. The serum concentration of MMP-8 was analyzed with immunofluorometric assay (IFMA), and those of MMP-9, MMP-13, and TIMP-1 were determined by enzyme-linked immunosorbent assays (ELISA). Clinical data were retrieved from patient records and survival data obtained from Statistics Finland.
The overall cumulative disease-specific survival was 69% at 1 year, 50% at 2 years, and 33% at 5 years. Kaplan-Meier overall survival analysis showed that patients with low concentrations of serum MMP-8 or TIMP-1 had a statistically significantly better overall survival than patients with high concentrations of serum MMP-8 or TIMP-1 (P=0.013 and P=0.003). Interestingly, the overall survival in patients with high MMP-9/TIMP-1 ratio was statistically significantly better than in those patients with low MMP-9/TIMP-1 ratio (P=0.004).
Our results suggest that serum MMP-8, TIMP-1, and the ratio of MMP-9/TIMP-1 might be useful adjuncts as predictors of prognosis in patients with HCC.
肝细胞癌（HCC）的预后预测较为困难。本研究旨在评估血清 MMP-8、-9、-13 和 TIMP-1 对 HCC 患者预后的预测价值。
回顾性分析了 134 例 HCC 患者的预处理血清样本。采用免疫荧光分析（IFMA）检测 MMP-8 血清浓度，采用酶联免疫吸附试验（ELISA）检测 MMP-9、MMP-13 和 TIMP-1 血清浓度。临床数据取自患者病历，生存数据取自芬兰统计局。
所有患者的 1 年累积疾病特异性生存率为 69%，2 年生存率为 50%，5 年生存率为 33%。Kaplan-Meier 总体生存分析显示，血清 MMP-8 或 TIMP-1 浓度较低的患者总体生存明显优于血清 MMP-8 或 TIMP-1 浓度较高的患者（P=0.013 和 P=0.003）。有趣的是，MMP-9/TIMP-1 比值较高的患者的总体生存率明显优于 MMP-9/TIMP-1 比值较低的患者（P=0.004）。
我们的研究结果表明，血清 MMP-8、TIMP-1 以及 MMP-9/TIMP-1 比值可能是预测 HCC 患者预后的有用指标。
